Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 7, 2010Molecular Cancer TherapeuticsOpen Access

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

NRN.V. RajeshkumarIGIgnacio Garrido‐LagunaAJAna De Jesus‐Acosta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rajeshkumar et al. (2010) studied this question.

synapsesocial.com/papers/6aae400edb1bec644ddc3bdahttps://doi.org/10.1158/1535-7163.mct-10-0893
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pancreatic Cancer2010 · 2,593 citations
  2. 2A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model2010 · 89 citations
  3. 3Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib2004 · 11,594 citations
  4. 4Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses2008 · 4,072 citations
  5. 5Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.1997 · 5,942 citations